Edgewise Therapeutics' (EWTX) management strongly believes that atrial fibrillation reported by some patients in a phase 2 study was not driven by EDG-7500 as there is no correlation between the cases and higher exposure to the drug, RBC Capital Markets said in a note on Wednesday.
The biopharmaceutical company reported Wednesday "positive" results for the phase 2 trial evaluating EDG-7500 in patients with obstructive or nonobstructive hypertrophic cardiomyopathy and said the most frequent adverse events were dizziness, upper respiratory tract infection and atrial fibrillation. Almost all of the adverse events were mild to moderate in severity, Edgewise said.
RBC analysts said they still recognize a potential risk that atrial fibrillation could be drug-related, but added they believe future data sets including 12-week data due in H2 "should help provide evidence that '7500 is not a driver of afib."
The firm has an outperform, speculative risk rating on the stock and cut its price target to $52 from $56.
Shares were down over 12% in recent trading.
Price: 13.64, Change: -1.88, Percent Change: -12.11
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。